MolecularMD-Logo_Color_Twitter.png
Sysmex and MolecularMD Commence Global Partnership to Address the Challenges in Companion Diagnostics Development and Commercialization
November 28, 2018 03:00 ET | MolecularMD
PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), a Japanese in vitro diagnostics company, and...
gmi 2018.png
Precision Medicine Market will see 10%+ CAGR to cross USD 96.6 billion by 2024: Global Market Insights, Inc.
November 15, 2018 05:00 ET | Global Market Insights, Inc
Sellbyville, Delaware, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Global Precision Medicine Market will cross USD 96.6 billion by 2024; according to a new research report by Global Market Insights, Inc....
MolecularMD-Logo_Color_Twitter.png
First quantitative diagnostic test validated for Treatment-Free Remission for Eligible Patients with Ph+ CML-CP Treated with Tasigna® Cleared by Health Canada
November 13, 2018 00:00 ET | MolecularMD
PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation received regulatory approval from Health Canada for the MRDx® BCR-ABL Test, a quantitative diagnostic...
logo 02.jpg
Companion Diagnostics Market USD 12,600 Million Valuation to Surpass till 2023 – Says Market Research Future
August 30, 2018 11:03 ET | Market Research Future
Pune, India, Aug. 30, 2018 (GLOBE NEWSWIRE) -- The Latest Study Conducted by Market Research Future® (MRFR) reveals that the Companion Diagnostics Market will surpass a valuation of USD 12,600 Mn by...
MolecularMD-Logo_Color_Twitter.png
MolecularMD and Genoptix Enter into a Definitive Agreement  to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®
June 04, 2018 00:30 ET | MolecularMD
PORTLAND, Ore. and CARLSBAD, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation and Genoptix, Inc. announced today that they have entered into an exclusive agreement to market and...
treos logo.jpg
Investigators Dose First Patient in Phase 1 Study of Treos Bio’s PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer
May 14, 2018 08:15 ET | Treos Bio Corp.
SAN FRANCISCO and LONDON, May 14, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...
treos logo.jpg
Treos Bio Names Gábor Illés as Its Chief Financial Officer
April 03, 2018 08:15 ET | Treos Bio Corp.
SAN FRANCISCO and LONDON, April 03, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...
Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor
March 14, 2018 07:30 ET | Exosome Diagnostics
Boston, MA, March 14, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., a market leader in liquid biopsy and the world’s first exosome-based diagnostics company announces a collaboration...
Treos Bio Announces FDA Approval of IND of Its First PolyPEPI™ Precision Cancer Vaccine for Metastatic Colorectal Cancer
January 24, 2018 08:15 ET | Treos Bio Corp.
SAN FRANCISCO and LONDON, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...
Exosome Diagnostics Places Early Access Shahky™ Exosomal Protein Detection System at MGH Center for Systems Biology
January 09, 2018 07:46 ET | Exosome Diagnostics
Waltham, MA, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has placed an Early Access version of its commercial Shahky system, which quantitively measures exosomal proteins, at...